清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

离格 医学 放射治疗 肺癌 阶段(地层学) 打开标签 外科 薄壁组织 放射外科 内科学 放射科 肿瘤科 随机对照试验 癌症 病理 免疫疗法 古生物学 生物
作者
Joe Y. Chang,Steven H. Lin,Wenli Dong,Zhongxing Liao,Saumil Gandhi,Carl M. Gay,Jianjun Zhang,Stephen G. Chun,Yasir Y. Elamin,Frank V. Fossella,George R. Blumenschein,Tina Cascone,Xiuning Le,Jenny Vu Pozadzides,Anne S. Tsao,Vivek Verma,James W. Welsh,Aileen B. Chen,Mehmet Altan,Reza J. Mehran
出处
期刊:The Lancet [Elsevier BV]
卷期号:402 (10405): 871-881 被引量:121
标识
DOI:10.1016/s0140-6736(23)01384-3
摘要

Background Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or distant relapses, or both, are common. Immunotherapy reduces recurrence and improves survival in people with stage III NSCLC after chemoradiotherapy, but its utility in stage I and II cases is unclear. We therefore conducted a randomised phase 2 trial of SABR alone compared with SABR with immunotherapy (I-SABR) for people with early-stage NSCLC. Methods We did an open-label, randomised, phase 2 trial comparing SABR to I-SABR, conducted at three different hospitals in TX, USA. People aged 18 years or older with histologically proven treatment-naive stage IA–IB (tumour size ≤4 cm, N0M0), stage IIA (tumour size ≤5 cm, N0M0), or stage IIB (tumour size >5 cm and ≤7 cm, N0M0) as per the American Joint Committee on Cancer version 8 staging system or isolated parenchymal recurrences (tumour size ≤7 cm) NSCLC (TanyNanyM0 before definitive surgery or chemoradiotherapy) were included in this trial. Participants were randomly assigned (1:1; using the Pocock & Simon method) to receive SABR with or without four cycles of nivolumab (480 mg, once every 4 weeks, with the first dose on the same day as, or within 36 h after, the first SABR fraction). This trial was unmasked. The primary endpoint was 4-year event-free survival (local, regional, or distant recurrence; second primary lung cancer; or death). Analyses were both intention to treat (ITT) and per protocol. This trial is registered with ClinicalTrials.gov (NCT03110978) and is closed to enrolment. Findings From June 30, 2017, to March 22, 2022, 156 participants were randomly assigned, and 141 participants received assigned therapy. At a median 33 months' follow-up, I-SABR significantly improved 4-year event-free survival from 53% (95% CI 42–67%) with SABR to 77% (66–91%; per-protocol population, hazard ratio [HR] 0·38; 95% CI 0·19–0·75; p=0·0056; ITT population, HR 0·42; 95% CI 0·22–0·80; p=0·0080). There were no grade 3 or higher adverse events associated with SABR. In the I-SABR group, ten participants (15%) had grade 3 immunologial adverse events related to nivolumab; none had grade 3 pneumonitis or grade 4 or higher toxicity. Interpretation Compared with SABR alone, I-SABR significantly improved event-free survival at 4 years in people with early-stage treatment-naive or lung parenchymal recurrent node-negative NSCLC, with tolerable toxicity. I-SABR could be a treatment option in these participants, but further confirmation from a number of currently accruing phase 3 trials is required. Funding Bristol-Myers Squibb and MD Anderson Cancer Center Alliance, National Cancer Institute at the National Institutes of Health through Cancer Center Core Support Grant and Clinical and Translational Science Award to The University of Texas MD Anderson Cancer Center.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小苹果发布了新的文献求助10
5秒前
土拨鼠完成签到 ,获得积分10
23秒前
量子星尘发布了新的文献求助10
30秒前
平常的三问完成签到 ,获得积分10
37秒前
zhuosht完成签到 ,获得积分10
46秒前
nengzou完成签到 ,获得积分10
48秒前
1437594843完成签到 ,获得积分10
49秒前
liu完成签到 ,获得积分10
51秒前
橙汁摇一摇完成签到 ,获得积分10
1分钟前
虞无声完成签到,获得积分10
1分钟前
zhao完成签到 ,获得积分10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
龙猫爱看书完成签到,获得积分10
1分钟前
研友_Ljqal8完成签到,获得积分10
1分钟前
1分钟前
发个15分的完成签到 ,获得积分10
1分钟前
badbaby完成签到 ,获得积分10
1分钟前
2分钟前
量子星尘发布了新的文献求助10
2分钟前
敏感人杰发布了新的文献求助10
2分钟前
2分钟前
innocence2000完成签到 ,获得积分10
2分钟前
2分钟前
oldchen完成签到 ,获得积分10
2分钟前
violetlishu完成签到 ,获得积分10
2分钟前
2分钟前
回首不再是少年完成签到,获得积分0
2分钟前
火星人完成签到 ,获得积分10
2分钟前
Gary完成签到 ,获得积分10
2分钟前
淡淡醉波wuliao完成签到 ,获得积分10
2分钟前
醉熏的千柳完成签到 ,获得积分10
2分钟前
宇文雨文发布了新的文献求助10
3分钟前
朴子完成签到 ,获得积分10
3分钟前
3分钟前
3分钟前
宇文雨文完成签到,获得积分10
3分钟前
唐诗阅完成签到,获得积分10
3分钟前
量子星尘发布了新的文献求助30
3分钟前
千帆破浪完成签到 ,获得积分10
3分钟前
3分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976735
求助须知:如何正确求助?哪些是违规求助? 3520825
关于积分的说明 11204846
捐赠科研通 3257602
什么是DOI,文献DOI怎么找? 1798771
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806648